Translational Medicine Academy

25/05/2026

Dr. Alicia Uijl discusses the growing burden of heart failure in an ageing, multimorbid population and how increasing clinical complexity is driving the need for new analytical approaches.

The session highlights the role of artificial intelligence in leveraging large volumes of routinely collected electronic health record data to better understand heart failure phenotypes, risk, and outcomes in clinical practice.

She further outlines key machine learning approaches, including supervised and unsupervised learning, and their applications in risk prediction, decision support, and data-driven classification in heart failure care.

Watch on demand: https://lnkd.in/gcND4mea

23/05/2026

Heart failure care evolves when guidelines move beyond publications and into daily clinical decision-making.

e-SPACE Heart Failure 2026 brings together a world-leading international faculty to explore GDMT implementation, patient profiling, emerging therapies, devices, and real-world strategies designed to improve better patient outcomes across the heart failure spectrum.

Save the Date: 23–24 October 2026
Join a global virtual programme translating evidence into practice: https://tinyurl.com/2unz26ce

20/05/2026

Our session at was a tremendous success, bringing together cardiologists and heart failure experts for a high-level EBAC-accredited educational session on Innovative Approaches in the Management of Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) in the Era of Guideline-Directed Medical Therapy (GDMT).

Strong engagement and full attendance reflected the growing clinical focus on advancing heart failure care beyond GDMT, with discussions centred on emerging therapeutic and device-based strategies, including interatrial shunt therapy and device management approaches.

The session featured insights from an international faculty addressing unmet clinical needs, patient selection considerations, and the balance of risks and benefits when integrating novel interventions into modern HFrEF management.

Thank you to all attendees and faculty for contributing to an engaging and impactful scientific exchange at HFA 2026.

Stay tuned for session highlights and upcoming educational updates.
https://www.tmacademy.org/

20/05/2026

LDL-C management continues to present a significant gap in primary cardiovascular prevention, despite its well-established role in long-term risk reduction.

This upcoming live webinar brings together international experts to explore how earlier intervention and more intensive lipid-lowering strategies may reshape preventive care in clinical practice.

Key focus areas include the LDL-C treatment gap, the benefits of early LDL-C lowering, and practical implementation of a “strike early, strike strong” approach, alongside the role of single-pill combinations in improving adherence and outcomes.

Register to join the discussion: https://www.p2pmd.net/cmvd-ice-2

18/05/2026

In this Meet the Experts session from e-SPACE Cardio-Renal-Metabolic 2026, Prof. Carol Po***ck and Prof. Mark Petrie explore why earlier diagnosis and intervention in CKM syndrome is becoming increasingly critical in improving patient outcomes.

The discussion highlights the growing shift toward CKM staging, from early metabolic risk through to overt cardiovascular and renal disease, and how this framework is reshaping risk identification and clinical decision-making in heart failure and diabetes populations.

With insights into early screening strategies and the importance of timely heart failure detection, the session reinforces a key message: earlier action changes outcomes.

Missed it? Watch on demand: https://www.espace-crm.org/2026

18/05/2026

Dyslipidemia remains a major driver of cardiovascular risk, with persistent gaps in LDL-C control in primary prevention.

Join leading international experts for a focused scientific discussion on whether current strategies are sufficient, and how earlier, more intensive lipid-lowering approaches may improve long-term outcomes.

Key topics include:
• The LDL-C treatment gap
• Clinical value of early LDL-C lowering
• A proactive “strike early, strike strong” approach
• Role of single-pill combination strategies in practice

Register now to secure your place: https://www.p2pmd.net/cmvd-ice-2

17/05/2026

On World Hypertension Day, we highlight one of the most critical and often under-recognised drivers of heart failure.

At Translational Medicine Academy, we focus on bridging evidence and clinical practice through multidisciplinary education across cardiovascular, renal, metabolic, and related disease areas, including e-SPACE Heart Failure.

Hypertension is a major contributor to the development and progression of heart failure, often acting silently before structural and symptomatic disease becomes evident.
Early detection and effective management remain essential to reduce long-term cardiovascular risk and improve patient outcomes.

Explore more initiatives advancing integrated cardiovascular care: https://www.tmacademy.org/

16/05/2026

At , the EBAC-accredited educational session on Left Ventricular (LV) Unloading: From Acute Treatment to Heart Recovery was a huge success, bringing together cardiologists and heart failure specialists for a high-level scientific exchange.

Strong engagement and full attendance highlighted the growing clinical interest in strategies that support haemodynamic stabilisation, myocardial recovery, and improved long-term outcomes across the heart failure continuum.

The session featured valuable perspectives from an international faculty, focusing on clinical evidence, patient management considerations, and the evolving role of LV unloading from acute care settings through to heart recovery and ongoing disease management.

Thank you to all attendees and faculty for contributing to an engaging and impactful scientific discussion at HFA 2026.

Stay tuned for session highlights and future updates: https://www.tmacademy.org/

14/05/2026

HFpEF care is advancing, but implementation gaps remain.
Prof. Mehmet B. Yılmaz and Prof. Ana María Cebrián Cuenca explore how to bridge evidence and practice.

Join the session at ECO 2026. https://tinyurl.com/yc38ym3j

iCARDIO arrives at ECO 2026 with a focused look at where HFpEF care is moving, and where the real gaps still remain.

From pharmacological advances, including guideline-directed therapy with SGLT2 inhibitors and emerging incretin-based approaches, to the practical realities of diagnosing HFpEF in primary care, this session connects evidence with implementation.

Together, Prof. Mehmet B. Yılmaz and Prof. Ana María Cebrián Cuenca highlight what it takes to move from treatment potential to real-world delivery across healthcare settings.

A focused step forward in bridging pharmacology and primary care in obesity-related HFpEF.

Friday, 15 May 2026
09:30 – 11:00
Hall 6, Istanbul Congress Center

Save this session: https://tinyurl.com/yc38ym3j

14/05/2026

iCARDIO makes its global debut at ECO 2026; moving obesity-related HFpEF from theory to implementation.

Join the session and be part of the discussion: https://tinyurl.com/yc38ym3j

iCARDIO makes its global debut at ECO 2026 - Istanbul.

This is where the conversation on obesity-related HFpEF shifts from theory to implementation.

We start with the biology, how excess adiposity drives heart failure through metabolic dysfunction, inflammation, insulin resistance, and haemodynamic stress. Then we move into what this means in practice: how to diagnose earlier, think in phenotypes, and deliver care that is truly multidisciplinary.

Prof. Donna H. Ryan explores why obesity must be treated as a disease at the centre of HFpEF outcomes.
Prof. Naveed Sattar translates the iCARDIO 2025 Guidelines into practical, integrated care pathways across healthcare settings.

A global debut focused on one thing: turning evidence into care that can actually be delivered.

Friday, 15 May 2026
09:30 – 11:00
Hall 6, Istanbul Congress Center

Don’t miss this session: https://tinyurl.com/yc38ym3j

12/05/2026

In May, obesity and its role within cardio-renal-metabolic disease is being extensively discussed at EASO 2026, reflecting its growing recognition as a central driver of conditions such as HFpEF and broader metabolic dysfunction.

These evolving conversations were also a key focus at e-SPACE Cardio-Renal-Metabolic 2026, where leading experts explored how obesity intersects with heart failure, diabetes, and
kidney disease within the CRM continuum.

A dedicated obesity-focused session highlighted the clinical relevance of weight management, metabolic therapies, and their impact on obesity-related HFpEF, reinforcing the need for earlier, integrated intervention strategies across specialties.

Missed the discussions? Watch e-SPACE CRM 2026 on demand: https://espacecrm.tmacademy.org/